How does public policy impact cervical screening and vaccination strategies?

Thomas J. Herzog, Warner K. Huh, Mark H. Einstein

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objectives: To examine the current approaches to cervical screening and points to consider for improving HPV vaccination acceptance and uptake in the US. Methods: An expert forum was conducted September 12-13, 2008, by the Society of Gynecologic Oncologists including 56 experts in cervical cancer and titled "Future Strategies of Cervical Cancer Prevention: What Do We Need to Do Now to Prepare?". Results: Cervical cancer prevention has primarily relied on screening paradigms but vaccination against human papillomavirus (HPV), the cause of the disease, is a primary preventative measure that has been recommended by all cervical cancer screening stakeholders. Guidelines for vaccination are developed by national advisory groups, but successful implementation requires a supportive infrastructure and the cooperation of providers, clinicians, and patients. HPV vaccination has been available in the United States (US) since 2006 and screening practices have been updated to also include HPV genotyping. However, many clinicians fail to adhere to the guidelines for HPV testing (and HPV co-testing) as part of cervical cancer screening, and vaccination coverage has been poor among females aged 11 and 12, the group for which vaccination is recommended by all organizations. Conclusions: The data reviewed and presented in this session of the "Future Strategies of Cervical Cancer Prevention. What Do We Need to do Now to Prepare?". The Forum suggests that the policies influencing HPV vaccination and screening need to be reassessed at multiple levels in order to achieve more effective implementation and regular use.

Original languageEnglish (US)
Pages (from-to)175-180
Number of pages6
JournalGynecologic Oncology
Volume119
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Public Policy
Uterine Cervical Neoplasms
Vaccination
Early Detection of Cancer
Guidelines
Organizations

Keywords

  • Cervical cancer
  • Screening
  • Vaccination

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology
  • Medicine(all)

Cite this

How does public policy impact cervical screening and vaccination strategies? / Herzog, Thomas J.; Huh, Warner K.; Einstein, Mark H.

In: Gynecologic Oncology, Vol. 119, No. 2, 2010, p. 175-180.

Research output: Contribution to journalArticle

Herzog, Thomas J. ; Huh, Warner K. ; Einstein, Mark H. / How does public policy impact cervical screening and vaccination strategies?. In: Gynecologic Oncology. 2010 ; Vol. 119, No. 2. pp. 175-180.
@article{df414ea0949c4756a7dce85fde59cf8f,
title = "How does public policy impact cervical screening and vaccination strategies?",
abstract = "Objectives: To examine the current approaches to cervical screening and points to consider for improving HPV vaccination acceptance and uptake in the US. Methods: An expert forum was conducted September 12-13, 2008, by the Society of Gynecologic Oncologists including 56 experts in cervical cancer and titled {"}Future Strategies of Cervical Cancer Prevention: What Do We Need to Do Now to Prepare?{"}. Results: Cervical cancer prevention has primarily relied on screening paradigms but vaccination against human papillomavirus (HPV), the cause of the disease, is a primary preventative measure that has been recommended by all cervical cancer screening stakeholders. Guidelines for vaccination are developed by national advisory groups, but successful implementation requires a supportive infrastructure and the cooperation of providers, clinicians, and patients. HPV vaccination has been available in the United States (US) since 2006 and screening practices have been updated to also include HPV genotyping. However, many clinicians fail to adhere to the guidelines for HPV testing (and HPV co-testing) as part of cervical cancer screening, and vaccination coverage has been poor among females aged 11 and 12, the group for which vaccination is recommended by all organizations. Conclusions: The data reviewed and presented in this session of the {"}Future Strategies of Cervical Cancer Prevention. What Do We Need to do Now to Prepare?{"}. The Forum suggests that the policies influencing HPV vaccination and screening need to be reassessed at multiple levels in order to achieve more effective implementation and regular use.",
keywords = "Cervical cancer, Screening, Vaccination",
author = "Herzog, {Thomas J.} and Huh, {Warner K.} and Einstein, {Mark H.}",
year = "2010",
doi = "10.1016/j.ygyno.2010.08.021",
language = "English (US)",
volume = "119",
pages = "175--180",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - How does public policy impact cervical screening and vaccination strategies?

AU - Herzog, Thomas J.

AU - Huh, Warner K.

AU - Einstein, Mark H.

PY - 2010

Y1 - 2010

N2 - Objectives: To examine the current approaches to cervical screening and points to consider for improving HPV vaccination acceptance and uptake in the US. Methods: An expert forum was conducted September 12-13, 2008, by the Society of Gynecologic Oncologists including 56 experts in cervical cancer and titled "Future Strategies of Cervical Cancer Prevention: What Do We Need to Do Now to Prepare?". Results: Cervical cancer prevention has primarily relied on screening paradigms but vaccination against human papillomavirus (HPV), the cause of the disease, is a primary preventative measure that has been recommended by all cervical cancer screening stakeholders. Guidelines for vaccination are developed by national advisory groups, but successful implementation requires a supportive infrastructure and the cooperation of providers, clinicians, and patients. HPV vaccination has been available in the United States (US) since 2006 and screening practices have been updated to also include HPV genotyping. However, many clinicians fail to adhere to the guidelines for HPV testing (and HPV co-testing) as part of cervical cancer screening, and vaccination coverage has been poor among females aged 11 and 12, the group for which vaccination is recommended by all organizations. Conclusions: The data reviewed and presented in this session of the "Future Strategies of Cervical Cancer Prevention. What Do We Need to do Now to Prepare?". The Forum suggests that the policies influencing HPV vaccination and screening need to be reassessed at multiple levels in order to achieve more effective implementation and regular use.

AB - Objectives: To examine the current approaches to cervical screening and points to consider for improving HPV vaccination acceptance and uptake in the US. Methods: An expert forum was conducted September 12-13, 2008, by the Society of Gynecologic Oncologists including 56 experts in cervical cancer and titled "Future Strategies of Cervical Cancer Prevention: What Do We Need to Do Now to Prepare?". Results: Cervical cancer prevention has primarily relied on screening paradigms but vaccination against human papillomavirus (HPV), the cause of the disease, is a primary preventative measure that has been recommended by all cervical cancer screening stakeholders. Guidelines for vaccination are developed by national advisory groups, but successful implementation requires a supportive infrastructure and the cooperation of providers, clinicians, and patients. HPV vaccination has been available in the United States (US) since 2006 and screening practices have been updated to also include HPV genotyping. However, many clinicians fail to adhere to the guidelines for HPV testing (and HPV co-testing) as part of cervical cancer screening, and vaccination coverage has been poor among females aged 11 and 12, the group for which vaccination is recommended by all organizations. Conclusions: The data reviewed and presented in this session of the "Future Strategies of Cervical Cancer Prevention. What Do We Need to do Now to Prepare?". The Forum suggests that the policies influencing HPV vaccination and screening need to be reassessed at multiple levels in order to achieve more effective implementation and regular use.

KW - Cervical cancer

KW - Screening

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=77957724472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957724472&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.08.021

DO - 10.1016/j.ygyno.2010.08.021

M3 - Article

VL - 119

SP - 175

EP - 180

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -